ACADIA Pharmaceuticals Inc.
ACAD
$25.13
-$0.32-1.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.34% | 18.70% | 12.36% | 18.28% | 46.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.34% | 18.70% | 12.36% | 18.28% | 46.44% |
| Cost of Revenue | 4.47% | 19.40% | 44.78% | -50.19% | 42.63% |
| Gross Profit | 12.46% | 18.23% | -6.38% | 311.17% | 48.98% |
| SG&A Expenses | 14.05% | 17.02% | 16.70% | 20.95% | 21.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.77% | 18.05% | 28.82% | -24.35% | 30.41% |
| Operating Income | 6.36% | 26.82% | -80.00% | 180.56% | 902.21% |
| Income Before Tax | 8.15% | 32.27% | 305.73% | 174.42% | 486.19% |
| Income Tax Expenses | 257.11% | 97.71% | 384.59% | -53.65% | -27.46% |
| Earnings from Continuing Operations | -20.14% | 14.69% | 213.87% | 150.27% | 2,897.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.14% | 14.69% | 213.87% | 150.27% | 2,897.22% |
| EBIT | 6.36% | 26.82% | -80.00% | 180.56% | 902.21% |
| EBITDA | 6.97% | 7.25% | -66.64% | 187.62% | 587.24% |
| EPS Basic | -21.22% | 13.23% | 210.58% | 149.75% | 2,866.18% |
| Normalized Basic EPS | 6.62% | 30.61% | -58.31% | 201.92% | 477.78% |
| EPS Diluted | -20.55% | 10.00% | 213.27% | 149.35% | 2,841.18% |
| Normalized Diluted EPS | 6.58% | 31.35% | -57.94% | 201.81% | 482.50% |
| Average Basic Shares Outstanding | 1.37% | 1.22% | 1.05% | 1.06% | 1.28% |
| Average Diluted Shares Outstanding | 1.51% | 0.63% | 0.11% | 1.18% | 0.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |